Search

everythinglearnresearchcommunity

for

Search:↓

A 26-year-old is experiencing hair thinning and has received conflicting diagnoses of androgenetic alopecia and telogen effluvium. They are considering treatments like dutasteride, oral and topical minoxidil, and are unsure whether to start treatment or pursue further diagnosis like a scalp biopsy.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

A 30-year-old male, 19 days post-hair transplant, is experiencing normal shedding and is concerned about hair loss. He is taking Dutasteride and Minoxidil tablets daily and is advised to trust the process as shedding is a typical phase.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.

The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A user who underwent a hair transplant in Istanbul to reduce balding, and the discussion of various treatments such as finasteride and growth hormone for preventing further hair loss.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

A 22-year-old experiencing intense hair loss across the scalp seeks advice, considering factors like nutrition and genetics. Suggestions include checking vitamin, mineral, and thyroid levels.

The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.

The user experienced hair loss due to androgenic alopecia and chose to use essential oils (rosemary and peppermint) and microneedling instead of minoxidil or finasteride. They reported positive results after 24 days and plan to continue with these treatments.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

A 28-year-old man had a hair transplant in India, choosing not to start finasteride due to past side effects with other medications but will use minoxidil for six months post-surgery. He researched and selected a clinic in Mumbai with a high reputation, underwent a 9-hour procedure for $965, and is optimistic about the results.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

A 20-year-old experiencing hair loss since age 16 is using finasteride and minoxidil and is considering future hair transplants. Discussions include the potential for multiple transplants, the use of body hair for coverage, and the importance of treatments like dutasteride and scalp micropigmentation for maintaining hair density.

A 24-year-old is considering a hair transplant but is hesitant due to cost and finding his shaved head looks better than expected. He plans to try finasteride to improve hair density after unsuccessful attempts with minoxidil and dutasteride.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.